Bluejay Diagnostics Raises $3.7 Million in Strategic Warrant Inducement Transaction

$BJDX

Bluejay Diagnostics, Inc. (NASDAQ: BJDX), an innovator in medical technology, has announced it has raised approximately $3.7 million in gross proceeds through a warrant inducement transaction. The deal involved institutional investors who are existing warrant holders, exercising their rights to purchase 1,085,106 shares of common stock at a reduced exercise price of $3.42 per share.

Aegis Capital Corp. acted as the exclusive financial advisor, facilitating a streamlined process that aligned closely with market dynamics. Legal counsel for the transaction was provided by Hogan Lovells US LLP on behalf of Bluejay and Kaufman & Canoles, PC representing Aegis Capital.

This capital raise is a strategic milestone for Bluejay, providing a financial boost to advance the company’s Symphony platform—a cutting-edge diagnostic system built to enhance patient outcomes in critical care environments. At the forefront of this platform is Bluejay’s lead product candidate: a 20-minute IL-6 Test for sepsis, which has the potential to transform sepsis triage and disease monitoring by delivering rapid, actionable results.

While the company remains optimistic about its growth trajectory, it acknowledges the inherent market risks and uncertainties that may influence future results. This development marks a significant moment in Bluejay’s journey, reflecting both its progress and potential in redefining rapid diagnostics in acute care settings. With strengthened financial backing and a clear clinical roadmap, Bluejay is positioning itself to drive meaningful innovation in healthcare delivery where speed, accuracy, and early intervention can make all the difference.

**DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE INTERPRETED AS INVESTMENT ADVICE. INVESTING INVOLVES RISK, INCLUDING THE POTENTIAL LOSS OF PRINCIPAL. READERS ARE ENCOURAGED TO CONDUCT THEIR OWN RESEARCH AND CONSULT WITH A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.**